Form 4: Aptevo Therapeutics Inc. Executive Kwon SoYoung Reports Stock Transactions
SEC Form 4 Filing
SVP, GC, BD & Corp Affairs Kwon SoYoung reports the vesting of Restricted Stock Units (RSUs) into common stock of Aptevo Therapeutics Inc.
Summary
- On May 31, 2024, Kwon SoYoung, SVP, GC, BD & Corp Affairs of Aptevo Therapeutics Inc., reported a transaction involving Restricted Stock Units (RSUs).
- 42 RSUs vested and converted into 588 shares of common stock.
- The reported transactions reflect adjustments for a 1-for-44 reverse stock split that occurred on March 5, 2024.
- The RSUs were granted on June 1, 2021, and vest in three approximately equal annual installments beginning on May 31, 2022.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation. It doesn't indicate a significant positive or negative outlook for the company.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The vesting of RSUs impacts shareholders by increasing the number of outstanding shares, potentially diluting ownership.
Key Dates
| Date | Description |
|---|---|
| June 1, 2021 | Reporting person was granted 5,500 (125 post-reverse split) RSUs. |
| May 31, 2022 | First vesting date of RSUs in three approximately equal annual installments. |
| March 5, 2024 | Aptevo Therapeutics effected a 1-for-44 reverse stock split. |
| May 31, 2024 | Transaction date: 42 RSUs vested and converted into common stock. |
| June 03, 2024 | Date of signature of the Form 4 filing. |
Keywords
Form 4, Aptevo Therapeutics, Kwon SoYoung, Restricted Stock Units, RSUs, Common Stock, Beneficial Ownership, Reverse Stock Split, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.